Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

EYPT

EyePoint Pharmaceuticals Inc

Dec 13 • 04:00PM ET

7.46

Dollar change -0.48
Percentage change -6.05	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: VTI IWM VXF VTWO VHT IWN IWO XPH IWC SMLF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	9.19%	Shs Outstand	53.52M	Perf Week	-14.35%
Market Cap	478.37M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	0.20%	Shs Float	48.60M	Perf Month	-30.67%
Income	-103.57M	PEG	-	EPS next Q	-0.50	Inst Own	104.23%	Short Float	19.03%	Perf Quarter	-15.61%
Sales	45.71M	P/S	10.47	EPS this Y	-22.02%	Inst Trans	7.51%	Short Ratio	10.69	Perf Half Y	-20.47%
Book/sh	4.09	P/B	1.83	EPS next Y	-16.04%	ROA	-44.94%	Short Interest	9.25M	Perf Year	-63.59%
Cash/sh	3.96	P/C	1.88	EPS next 5Y	-	ROE	-74.68%	52W Range	7.40 - 30.99	Perf YTD	-67.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.57%	ROI	-43.04%	52W High	-75.93%	Beta	1.48
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	69.47%	Gross Margin	91.48%	52W Low	0.81%	ATR (14)	0.67
Dividend Ex-Date	-	Current Ratio	5.50	EPS Y/Y TTM	24.76%	Oper. Margin	-255.88%	RSI (14)	33.60	Volatility	7.07% 7.41%
Employees	121	Debt/Eq	0.11	Sales Y/Y TTM	7.50%	Profit Margin	-226.57%	Recom	1.08	Target Price	33.45
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-63.94%	Payout	-	Rel Volume	0.89	Prev Close	7.94
Sales Surprise	0.91%	EPS Surprise	1.08%	Sales Q/Q	-30.77%	Earnings	Nov 07 BMO	Avg Volume	864.96K	Price	7.46
SMA20	-13.65%	SMA50	-23.87%	SMA200	-38.32%	Trades		Volume	767,924	Change	-6.05%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
08:35AM	Loading…
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%
12:16PM	EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss (Benzinga)
07:00AM	EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema (GlobeNewswire)
07:00AM	Loading…
Oct-24-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks) -7.35%
Oct-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +14.17%
Sep-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 07:00AM	EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors (GlobeNewswire)
Aug-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.90%
Aug-07-24 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:09AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-26-24 08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYU (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
07:00AM	Loading…
Jun-18-24 07:00AM	EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 (GlobeNewswire)
Jun-17-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 07:00AM	EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire) +6.18%
02:35AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com)
May-17-24 02:34AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com) -5.43%
May-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-24 02:34PM	EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges (GuruFocus.com)
May-08-24 01:54PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:48AM	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating (MT Newswires)
07:23AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
May-07-24 09:32AM	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating (MT Newswires) +5.98%
May-06-24 11:00AM	Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? (Benzinga) -43.26%
08:42AM	EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint (MT Newswires)
07:00AM	EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy (GlobeNewswire)
Apr-23-24 01:21PM	Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, RA Capital Management, Millennium Management, Biohaven Ltd (BHVN), EyePoint Pharmaceuticals Inc. (EYPT), and More (Insider Monkey)
Apr-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 07:00AM	EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists (GlobeNewswire)
Mar-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia)
Mar-08-24 09:31AM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:39PM	Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:25PM	EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 (GuruFocus.com)
12:53PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:30AM	Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics (Zacks)
07:20AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -7.46%
Feb-29-24 10:00AM	Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know (Zacks)
08:50AM	Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going (Zacks)
07:00AM	EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
04:19AM	20 Countries With Worst Vision Problems (Insider Monkey)
Feb-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +7.98%
Feb-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 12:00PM	Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice (Zacks)
Feb-13-24 09:55AM	Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet (Zacks)
08:50AM	Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength (Zacks)
Feb-03-24 04:20PM	EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Jan-31-24 07:00AM	EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 11:02PM	EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares (GuruFocus.com)
Jan-25-24 11:51PM	EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares (GuruFocus.com) +6.31%
Jan-24-24 07:01PM	EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares (GuruFocus.com)
Jan-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:14PM	EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares (GuruFocus.com) +11.79%
Jan-10-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema (GlobeNewswire) -5.78%
Dec-20-23 07:00AM	EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-23 12:45PM	Hedge Fund and Insider Trading News: Leon Cooperman, Christopher Hohn, Ken Griffin, D.E. Shaw, Ryman Hospitality Properties Inc (RHP), EyePoint Pharmaceuticals, Inc. (EYPT), and More (Insider Monkey) +7.84%
Dec-11-23 12:00PM	EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-08-23 04:01PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -9.58%
09:55AM	Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade (Zacks)
08:50AM	What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing' (Zacks)
Dec-07-23 01:07PM	Insider Sell Alert: Chief Corp Dev. & Strat. ... (GuruFocus.com) +9.46%
Dec-05-23 08:18PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire) +9.08%
09:18AM	EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data (Zacks)
Dec-04-23 04:06PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +177.46%
11:37AM	Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today? (InvestorPlace)
07:00AM	EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints (GlobeNewswire)
06:19AM	EyePoint sees stock surge on AMD drug trial data (BioPharma Dive)
Nov-21-23 09:55AM	Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect? (Zacks) -13.44%
Nov-16-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.62%
Nov-02-23 07:04PM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.31%
Nov-01-23 09:33AM	EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Results (GuruFocus.com) +20.27%
07:06AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Oct-31-23 07:00AM	EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023 (GlobeNewswire) +5.43%
Oct-30-23 07:00AM	EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023 (GlobeNewswire)
Oct-25-23 07:00AM	EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023 (GlobeNewswire) -14.21%
Oct-16-23 07:00AM	EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team (GlobeNewswire)
Sep-18-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.82%

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANTHONY P. ADAMIS	Director	Oct 23 '24	Proposed Sale	10.04	67,100	673,355		Oct 23 04:34 PM
David R. Guyer	Former Director	Oct 14 '24	Proposed Sale	8.92	36,975	329,817		Oct 15 11:58 AM
DICICCO WENDY F	Director	Aug 20 '24	Buy	7.79	2,567	19,997	9,967	Aug 21 04:32 PM
ANDO GORAN	Director	Aug 21 '24	Buy	7.95	5,000	39,750	13,150	Aug 21 04:01 PM
Zaderej Karen L.	Director	Aug 19 '24	Buy	7.98	12,500	99,750	16,500	Aug 21 04:01 PM
Lurker Nancy	Director	Aug 16 '24	Buy	7.88	3,173	25,003	97,635	Aug 20 04:04 PM
GUYER DAVID R	Director	Jul 12 '24	Option Exercise	3.34	9,775	32,646	13,475	Jul 16 04:24 PM
GUYER DAVID R	Director	Jul 12 '24	Sale	10.06	11,625	116,995	1,850	Jul 16 04:24 PM
Duker Jay S.	President and CEO	Jul 10 '24	Option Exercise	0.00	16,666	0	46,086	Jul 12 05:04 PM
Lurker Nancy	Executive Vice Chair	Jul 10 '24	Option Exercise	0.00	11,111	0	94,462	Jul 12 05:03 PM
Zaderej Karen L.	Director	Jul 11 '24	Option Exercise	0.00	2,000	0	4,000	Jul 12 05:00 PM
ADAMIS ANTHONY P	Director	Jun 23 '24	Option Exercise	0.00	2,000	0	4,000	Jun 25 04:16 PM
GUYER DAVID R	Director	Jun 03 '24	Option Exercise	3.34	9,775	32,646	15,325	Jun 04 04:28 PM
GUYER DAVID R	Director	Jun 03 '24	Sale	10.30	11,625	119,705	3,700	Jun 04 04:28 PM
Elston George	Chief Financial Officer	May 25 '24	Option Exercise	0.00	7,500	0	51,107	May 28 04:22 PM
GUYER DAVID R	Director	May 14 '24	Option Exercise	3.34	9,775	32,646	17,175	May 16 05:19 PM
GUYER DAVID R	Director	May 14 '24	Sale	12.65	11,625	147,045	5,550	May 16 05:19 PM
Cormorant Asset Management, LP	10% Owner	May 06 '24	Buy	11.86	850,000	10,081,721	8,325,000	May 08 04:23 PM
Cormorant Asset Management, LP	10% Owner	Apr 18 '24	Buy	18.03	581,765	10,489,446	7,475,000	Apr 22 04:00 PM
Paggiarino Dario A.	Chief Medical Officer	Mar 30 '24	Option Exercise	0.00	50,404	0	92,626	Apr 02 05:27 PM
Lurker Nancy	Executive Vice Chair	Feb 09 '24	Option Exercise	0.00	37,534	0	172,975	Feb 13 05:40 PM
Paggiarino Dario A.	Chief Medical Officer	Feb 09 '24	Option Exercise	0.00	10,800	0	47,305	Feb 13 05:39 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 09 '24	Option Exercise	0.00	9,967	0	48,572	Feb 13 05:38 PM
Elston George	Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	10,800	0	46,799	Feb 13 05:38 PM
Duker Jay S.	President and CEO	Feb 09 '24	Option Exercise	0.00	11,967	0	55,453	Feb 13 05:37 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 02 '24	Option Exercise	11.47	209	2,397	38,171	Feb 05 05:15 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 02 '24	Sale	28.49	209	5,954	37,962	Feb 05 05:15 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 26 '24	Option Exercise	13.06	49,325	644,047	85,830	Jan 30 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 26 '24	Sale	25.66	49,325	1,265,539	36,505	Jan 30 04:53 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 26 '24	Option Exercise	6.82	26,017	177,398	63,979	Jan 29 05:54 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 26 '24	Sale	25.38	26,017	660,370	37,962	Jan 29 05:54 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 25 '24	Option Exercise	13.02	600	7,809	37,105	Jan 29 05:51 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 25 '24	Sale	25.00	600	15,000	36,505	Jan 29 05:51 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 24 '24	Option Exercise	8.04	11,300	90,822	49,262	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 25 '24	Option Exercise	8.08	600	4,848	38,562	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 24 '24	Sale	25.01	11,300	282,621	37,962	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 25 '24	Sale	25.00	600	15,000	37,962	Jan 26 05:03 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 24 '24	Option Exercise	13.01	11,251	146,426	47,756	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 23 '24	Option Exercise	13.04	5,135	66,954	41,640	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 24 '24	Sale	25.01	11,251	281,415	36,505	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 23 '24	Sale	25.00	5,135	128,375	36,505	Jan 25 06:26 PM
Lurker Nancy	Executive Vice Chair	Jan 24 '24	Sale	24.98	29,956	748,250	135,441	Jan 25 06:24 PM
Lurker Nancy	Executive Vice Chair	Jan 23 '24	Sale	24.97	5,044	125,950	165,397	Jan 25 06:24 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 22 '24	Option Exercise	10.34	34,166	353,359	72,128	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 23 '24	Option Exercise	7.54	900	6,790	38,862	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 22 '24	Sale	22.62	34,166	772,691	37,962	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 23 '24	Sale	25.00	900	22,500	37,962	Jan 24 04:50 PM
Ocumension Therapeutics	Director	Jan 11 '24	Sale	19.45	1,910,500	37,159,225	100,221	Jan 16 06:55 PM
Liu Ye	Director	Jan 11 '24	Sale	19.45	1,910,500	37,159,225	100,221	Jan 16 06:01 PM
Cormorant Asset Management, LP	10% Owner	Jan 11 '24	Buy	19.75	750,000	14,812,500	6,893,235	Jan 11 04:00 PM
Cormorant Asset Management, LP	10% Owner	Jan 09 '24	Buy	21.32	105,000	2,238,600	6,143,235	Jan 11 04:00 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 08 '24	Option Exercise	3.26	22,913	74,696	59,418	Jan 10 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 08 '24	Sale	21.13	22,913	484,124	36,505	Jan 10 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	40,992	Jan 09 09:28 PM
Lurker Nancy	Executive Vice Chair	Jan 06 '24	Option Exercise	0.00	75,133	0	193,484	Jan 09 09:17 PM
Pine Michael Craig	Chief Corp Dev.&Strat. Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	19,628	Jan 09 09:11 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	42,109	Jan 09 09:09 PM
Duker Jay S.	President and CEO	Jan 06 '24	Option Exercise	0.00	20,793	0	50,014	Jan 09 09:07 PM
Elston George	Chief Financial Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	40,219	Jan 09 09:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EYPT

EyePoint Pharmaceuticals Inc

Upgrade your FINVIZ experience